#United States #BD #Franklin Lakes #Liverty #TIPS Stent

Transforming Treatment for Portal Hypertension: BD's Groundbreaking Liverty™ TIPS Stent Graft

In a significant advancement for liver disease management, BD (Becton, Dickinson and Company) has received CE Mark approval for its Liverty™ TIPS Stent Graft. This innovative device aims to improve care for patients suffering from portal hypertension across the European Union. Portal hypertension, a serious condition resulting from liver cirrhosis, leads to dangerous complications such as variceal bleeding and fluid accumulation, presenting a critical challenge within healthcare.

Understanding Portal Hypertension and Its Impacts

Cirrhosis affects an estimated 58 million individuals globally, leading to a variety of health complications. According to the Global Burden of Disease study, the prevalence of this condition underscores the urgent need for innovative treatment solutions. The Liverty™ TIPS Stent Graft is designed to alleviate symptoms by providing a reliable method to achieve lower portal pressures, thus enhancing blood flow and overall patient comfort.

Features of the Liverty™ TIPS Stent Graft

The Liverty™ TIPS Stent Graft showcases multiple features aimed at optimizing patient care:

• - Adjustable Inner Diameter: The device allows for a customizable 6–10 mm inner diameter, accommodating a range of patient needs.
• - Wide Range of Stent Lengths: This flexibility ensures that the device can be tailored for various anatomical requirements.
• - Advanced Delivery System: Its triaxial delivery system enables precise placement, which is crucial for effective treatment outcomes.
• - Self-Expanding Technology: The flexible nitinol frame automatically adjusts to the patient's unique physiology, guaranteeing a secure fit.

These features make the Liverty™ TIPS Stent Graft a valuable addition to current treatments, emphasizing individualized care.

Arch Clinical Trial Insights

BD's commitment to the safety and effectiveness of the Liverty™ TIPS Stent Graft is bolstered by data from the pivotal ARCH clinical trial. During this trial, the stent's performance was meticulously evaluated for managing complications arising from portal hypertension. At the upcoming Society of Interventional Radiology (SIR) Annual Scientific Meeting, Prof. Ziv Haskal, MD, the global principal investigator, will present the trial findings, marking a significant moment in advancing patient care through evidence-based practices.

Dr. Haskal expressed optimism about the implications of the Liverty™ TIPS Stent Graft, stating, “This device is a pivotal advancement in the management of portal hypertension complications. Its adjustable design empowers healthcare professionals to tailor treatments to individual patient needs more effectively.”

A Vision for the Future of Healthcare

BD is committed to supporting healthcare professionals and patients alike by delivering transformative medical technologies. The company's Purpose of advancing the world of health™ emphasizes a dedication to innovation that promotes better health outcomes globally. With a workforce of over 60,000 employees and a commitment to quality healthcare practices, BD continually strives to optimize clinical operations and enhance patient care.

As the healthcare landscape evolves, the launch of the Liverty™ TIPS Stent Graft marks a step forward in addressing the challenges of portal hypertension. Future developments will focus on increasing access to innovative solutions for patients, caregivers, and healthcare providers across Europe and beyond.

For more information about BD and its transformative healthcare solutions, visit bd.com. Connect with BD on LinkedIn, Twitter, and Instagram for updates and further insights.

In conclusion, as BD introduces the Liverty™ TIPS Stent Graft, the potential for improved care for patients facing the complexities of liver disease is more promising than ever, setting a new standard for interventional techniques in managing port hypertension.